首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

2058330

全球注射用胜肽類藥物市場：依藥物類別、給藥途徑、劑型、遞送系統、治療領域、通路及最終用戶分類－市場規模、產業趨勢、機會分析及2026-2035年預測

Global Injectable Peptides Drugs Market: By Drug Class, Route of Administration, Formulation Type, Delivery System, Therapeutic Area, Distribution Channel, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

出版日期: 2026年05月19日 | 出版商:

Astute Analytica | 英文 310 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球注射用胜肽類藥物市場持續強勁且永續地擴張，反映出各種慢性病和代謝性疾病對先進生物製藥日益成長的需求。 2025年，該市場規模約491億美元，預計2035年將達到約1,205.7億美元。 2026年至2035年預測期間內，複合年成長率預計為9.40%。這顯著的成長軌跡凸顯了臨床上對注射用胜肽類藥物作為現代治療策略核心組成部分的日益依賴。

推動此成長的主要動力是代謝性疾病治療，特別是糖尿病、肥胖症及相關內分泌疾病治療的快速進展。注射用胜肽製劑因其能夠模擬或增強天然生物過程，從而實現高度靶向和有效的治療效果，而日益受到重視。與傳統小分子藥物相比，這些治療方法已被廣泛認為是慢性病管理的首選方案，具有更高的療效、更高的患者反應率和更低的副作用。

顯著的市場趨勢

注射用胜肽類藥物市場競爭異常激烈，少數幾家大型製藥企業主導全球銷售，並推動治療方法創新。這些主要企業憑藉著強大的研發能力、完善的分銷網路、豐富的監管經驗以及對下一代肽類治療方法的持續投入，確立了其穩固的市場地位。

諾和諾德憑藉其先進的司Semaglutide注射療法，在重新定義肥胖症和代謝性疾病的治療方面發揮了變革性作用。禮來公司已成功將Tirzepatide療法商業化，並正在迅速擴大其全球企業發展。賽諾菲在傳統胰島素和荷爾蒙補充療法領域繼續保持著強勁的地位。

安進公司正策略性地投資於先進胜肽生物技術的研發，以擴大其在注射用胜肽市場的佔有率。Astra Zeneca則持續強化其心血管和代謝疾病治療產品組合，致力於透過先進的藥物研發改善患者預後。整體而言，這些領導企業的市場主導地位得益於持續創新、強大的臨床研發管線和全球商業性網路。

主要成長要素

全球注射用肽類藥物市場正經歷顯著成長，這主要得益於全球慢性代謝和內分泌疾病患者數量的不斷增加。需要持續治療的慢性疾病盛行率不斷上升，促使對注射用肽類藥物的需求強勁且持續。這些治療方法因其能夠調節荷爾蒙活性、改善代謝平衡並支持複雜疾病患者的長期疾病管理而被廣泛應用。預計到2025年，全球將有8.3億人患有糖尿病，這種慢性疾病的負擔十分沉重。

新機會的趨勢

目前的醫療處方趨勢對注射用胜肽製劑市場的成長和發展方向起著決定性作用。全球醫療體系中的醫護人員正逐步將處方行為轉向更先進、臨床療效更佳的胜肽製劑。這項轉變的促進因素包括治療效果的改善、患者依從性的提高，以及越來越多的臨床證據支持新一代注射用肽製劑在治療慢性代謝和內分泌疾病方面的有效性。

最佳化障礙

目前，營運瓶頸是限制全球注射用胜肽療法市場成長的主要阻礙因素。注射用胜肽療法的生產過程極為複雜，需要在嚴格控制的實驗室環境下精確合成長鏈胺基酸。這種複雜性要求具備先進的生物技術基礎設施、高度專業化的設備和精湛的科研人員。即使生產參數出現微小偏差，也會影響分子穩定性、純度和治療效果，因此，對於製藥公司而言，實現大規模、低成本的生產是一項巨大的挑戰。

市場動態和趨勢
- 成長要素
  - 慢性病和罕見病患疾病率增加
  - 創新和高價值特種胜肽
- 抑制因子
  - 高昂的製造成本和複雜的製造程序
  - 嚴格的監管要求
- 機會
  - 契約製造和CDMO夥伴關係
- 主要趨勢
  - 向個人化和標靶胜肽療法過渡
市場規模及預測，2020-2035年
- 藥物類別
  - 關鍵見解
    - 胰島素和胰島素類似物
    - GLP-1受體促效劑
    - 生長激素胜肽
    - 促性腺激素分泌釋放激素 (GnRH) 類似物
    - 生長抑制素類似物
    - 副甲狀腺素肽
    - 抑鈣素肽
    - 血管加壓素及其類似物
    - ACTH胜肽
    - 基於胜肽的抗癌藥物
    - 抗感染疾病胜肽類藥物
    - 其他胜肽類治療藥物
- 透過行政途徑
  - 關鍵見解
    - 皮下注射
    - 靜脈注射
    - 肌肉內注射
    - 椎管內注射
    - 其他注射途徑
- 依配方類型
  - 關鍵見解
    - 即用型注射劑
    - 冷凍乾燥注射劑
    - 緩釋/長效注射劑
- 透過行政途徑
  - 關鍵見解
    - 常規管瓶和安瓿
    - 預填充式注射器
    - 筆式注射器
    - 自動注射器
    - 靜脈輸液系統
- 按治療區域
  - 關鍵見解
    - 代謝性疾病
    - 內分泌疾病
    - 腫瘤學
    - 消化系統疾病
    - 骨質疏鬆症與骨骼疾病
    - 心血管疾病
    - 感染疾病
    - 罕見疾病
    - 其他
- 透過分銷管道
  - 關鍵見解
    - 醫院藥房
    - 零售藥房
    - 專科藥房
    - 網路藥房
- 最終用戶
  - 關鍵見解
    - 醫院
    - 專科診所
    - 門診部
    - 居家醫療
    - 研究和學術機構
- 按製造模型
- 按地區
  - 關鍵見解
    - 北美洲
      - 美國
      - 加拿大
      - 墨西哥
    - 歐洲
      - 西歐
        
        英國
        德國
        法國
        義大利
        西班牙
        其他西歐國家
      - 東歐
        
        波蘭
        俄羅斯
        其他東歐國家
    - 亞太地區
      - 中國
      - 印度
      - 日本
      - 韓國
      - 澳洲和紐西蘭
      - ASEAN
        
        印尼
        馬來西亞
        泰國
        新加坡
        其他東南亞國協
      - 其他亞太國家
    - 中東和非洲
      - UAE
      - 沙烏地阿拉伯
      - 南非
      - 其他中東和非洲國家
    - 南美洲
      - 阿根廷
      - 巴西
      - 其他南美國家

第6章：北美注射用胜肽類藥物市場分析

第7章：歐洲注射用胜肽類藥物市場分析

第8章：亞太地區注射用胜肽類藥物市場分析

第9章：中東和非洲注射用胜肽類藥物市場分析

第10章：南美洲注射用胜肽類藥物市場分析

第11章：公司簡介

AbbVie
AstraZeneca
Eli Lilly
Ferring
Ipsen
J & J
Merck
Novartis
Novo Nordisk
Sanofi
Takeda
Teva
Other Prominent Players

第12章附錄

簡介目錄

Product Code: AA05261796

The global injectable peptides drugs market is experiencing strong and sustained expansion, reflecting increasing demand for advanced biologic therapies across a wide range of chronic and metabolic diseases. In 2025, the market is valued at approximately USD 49.10 billion and is projected to reach around USD 120.57 billion by 2035, growing at a compound annual growth rate (CAGR) of 9.40% during the forecast period from 2026 to 2035. This significant growth trajectory highlights the rising clinical reliance on peptide-based injectable drugs as a core component of modern therapeutic strategies.

A major factor driving this expansion is the rapid advancement in metabolic disease treatment, particularly in conditions such as diabetes, obesity, and related endocrine disorders. Injectable peptide drugs have become increasingly important due to their ability to mimic or enhance natural biological processes, offering targeted and highly effective therapeutic outcomes. These treatments are widely recognized for their improved efficacy, better patient response rates, and reduced side effects compared to traditional small-molecule drugs, making them a preferred option in chronic disease management.

Noteworthy Market Developments

The injectable peptides drug market is characterized by intense competition, with a small group of leading pharmaceutical companies dominating global revenues and shaping therapeutic innovation. These top players hold strong positions due to their extensive research capabilities, established distribution networks, regulatory expertise, and continuous investment in next-generation peptide-based therapies.

Novo Nordisk has played a transformative role in redefining obesity and metabolic disease management through its advanced semaglutide-based injectable therapies. Eli Lilly and Company has rapidly expanded its global footprint through the successful commercialization of tirzepatide-based therapies. Sanofi continues to maintain a strong position in the conventional insulin and hormone replacement therapy segment.

Amgen is strategically investing in advanced peptide biotechnology research to expand its presence in the injectable peptides market. AstraZeneca continues to strengthen its cardiovascular and metabolic therapeutic portfolio, with a strong emphasis on improving patient outcomes through advanced drug development. Overall, the dominance of these leading pharmaceutical companies is driven by continuous innovation, strong clinical pipelines, and global commercial reach.

Core Growth Drivers

The global injectable peptides drugs market is experiencing substantial growth, largely driven by the expanding size of the global patient population affected by chronic metabolic and endocrine disorders. The increasing prevalence of long-term conditions that require ongoing therapeutic management has created a strong and sustained demand for injectable peptide-based treatments. These therapies are widely used due to their ability to regulate hormonal activity, improve metabolic balance, and support long-term disease control in patients with complex health conditions. In 2025, it is estimated that over 830 million people worldwide are living with diabetes, highlighting the immense scale of this chronic disease burden.

Emerging Opportunity Trends

Current medical prescription trends are playing a decisive role in shaping the growth and direction of the injectable peptides drugs market. Across global healthcare systems, medical professionals are steadily shifting their prescribing behavior toward more advanced and clinically effective peptide-based formulations. This transition is being driven by improved therapeutic outcomes, better patient adherence profiles, and increasing clinical evidence supporting the efficacy of next-generation injectable peptide drugs in managing chronic metabolic and endocrine disorders.

Barriers to Optimization

Operational bottlenecks are currently acting as a key constraint on the growth trajectory of the global injectable peptides drugs market. The manufacturing process for injectable peptide therapies is highly complex, requiring the precise synthesis of long amino acid chains under tightly controlled laboratory conditions. This level of complexity demands advanced biotechnological infrastructure, highly specialized equipment, and skilled scientific expertise. Even minor deviations in production parameters can affect molecular stability, purity, and therapeutic efficacy, making large-scale, cost-efficient manufacturing a significant challenge for pharmaceutical producers.

Detailed Market Segmentation

By drug class, the insulin and insulin analogs segment held a dominant position in the injectable peptide drugs market, accounting for approximately 35% of the global market share in 2025. This leadership reflects the essential and non-discretionary nature of insulin therapy in the management of diabetes, particularly for patients with type 1 diabetes and advanced stages of type 2 diabetes. Insulin remains a fundamental hormone replacement therapy required to regulate blood glucose levels and ensure basic metabolic function, making it one of the most consistently demanded therapeutic products worldwide.

By route of administration, subcutaneous injection emerged as the dominant method in the injectable peptide drugs market, accounting for approximately 70% of the global share in 2025. This leading position is primarily due to its practical advantages in terms of ease of use, patient convenience, and suitability for long-term therapeutic regimens. Subcutaneous delivery enables medications to be absorbed gradually through the fatty tissue beneath the skin, providing sustained drug release and stable therapeutic effects, which is particularly important for peptide-based drugs used in chronic disease management.

By therapeutic area, the diabetes and obesity management segment led the injectable peptide drugs market, accounting for the largest revenue share of approximately 45% in 2025. This dominant position reflects the rapidly growing global burden of metabolic disorders, which continue to place a significant strain on healthcare systems worldwide. The rising prevalence of type 2 diabetes, insulin resistance, and obesity-related complications has created sustained demand for advanced therapeutic solutions, particularly injectable peptide-based drugs that offer improved glycemic control, appetite regulation, and metabolic balance.

By distribution channel, hospital pharmacies emerged as the dominant segment in the injectable peptide drugs market, accounting for approximately 46% of total revenue share in 2025. Their leadership is largely attributed to their central role within institutional healthcare systems, where they serve as the primary point of dispensing for complex and high-value injectable therapies. Hospital pharmacies are especially critical for managing treatments that require precise dosing, specialized handling, and close clinical supervision, making them the preferred distribution channel for injectable peptide drugs used in both acute and chronic care settings.

Segment Breakdown

By Drug Class

Insulin & Insulin Analogs
GLP-1 Receptor Agonists
Growth Hormone Peptides
Gonadotropin-Releasing Hormone (GnRH) Analogs
Somatostatin Analogs
Parathyroid Hormone Peptides
Calcitonin Peptides
Vasopressin & Analogues
ACTH Peptides
Peptide-based Oncology Drugs
Anti-infective Peptide Drugs
Other Peptide Therapeutics

By Route of Administration

Subcutaneous Injection
Intravenous Injection
Intramuscular Injection
Intrathecal Injection
Other Injectable Routes

By Formulation Type

Ready-to-use Injectables
Lyophilized Injectables
Sustained/Extended-release Injectables

By Delivery System

Conventional Vials & Ampoules
Prefilled Syringes
Pen Injectors
Auto-injectors
Infusion-based Delivery Systems

By Therapeutic Area

Metabolic Disorders
Endocrine Disorders
Oncology
Gastrointestinal Disorders
Osteoporosis & Bone Disorders
Cardiovascular Diseases
Infectious Diseases
Rare Diseases
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies

By End User

Hospitals
Specialty Clinics
Ambulatory Care Centers
Homecare Settings
Research & Academic Institutes

By Manufacturing Model

In-house Manufacturing
Contract Manufacturing (CMOs/CDMOs)

By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

Geography Breakdown

North America led the injectable peptides drugs market in 2025, accounting for approximately 41% of the global share. This dominant position is largely supported by the region's advanced healthcare infrastructure, well-established pharmaceutical ecosystem, and strong reimbursement systems. Comprehensive health insurance frameworks across the United States and Canada significantly reduce the out-of-pocket burden for patients, making access to high-cost injectable peptide therapies more feasible.
Government-led healthcare initiatives across the region further contribute to market expansion by emphasizing early disease detection and preventive care strategies. Public health programs increasingly encourage routine screening and early diagnostic testing for chronic diseases such as diabetes, metabolic disorders, and hormonal imbalances, all of which are key therapeutic areas for injectable peptide drugs.
The presence of strong domestic pharmaceutical manufacturing and biotechnology capabilities also reinforces North America's leadership in this market. The region hosts a dense network of global pharmaceutical companies, biotech firms, and research institutions that specialize in peptide synthesis, drug formulation, and advanced molecular engineering. These capabilities support rapid drug development, efficient clinical trials, and large-scale commercialization of innovative injectable peptide therapies.

Leading Market Participants

AbbVie
AstraZeneca
Eli Lilly
Ferring
Ipsen
J & J
Merck
Novartis
Novo Nordisk
Sanofi
Takeda
Teva
The Medicines
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Injectable Peptides Drugs Market

Chapter 2. Report Description

2.1. Research Framework
- 2.1.1. Research Objective
- 2.1.2. Market Definitions
- 2.1.3. Market Segmentation
2.2. Research Methodology
- 2.2.1. Market Size Estimation
- 2.2.2. Qualitative Research
  - 2.2.2.1. Primary & Secondary Sources
- 2.2.3. Quantitative Research
  - 2.2.3.1. Primary & Secondary Sources
- 2.2.4. Breakdown of Primary Research Respondents, By Country
- 2.2.5. Data Triangulation
- 2.2.6. Assumption for Study

Chapter 3. Global Injectable Peptides Drugs Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Raw Materials & Sourcing
- 3.1.2. Manufacturers & CDMOs
- 3.1.3. Formulation & Injectable Preparation
- 3.1.4. Packaging & Labelling
- 3.1.5. Distribution Channels & Logistics
- 3.1.6. End-User Applications
- 3.1.7. Regulatory & Compliance Oversight
3.2. Industry Outlook
- 3.2.1. Pharmaceutical Industry Outlook
- 3.2.2. Pipeline Analysis
- 3.2.3. Outsourcing & CDMO Expansion
- 3.2.4. Regulatory & Compliance Evolution
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Growth and Outlook
- 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
3.6. Market Attractiveness Analysis
3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Injectable Peptides Drugs Market Analysis

5.1. Market Dynamics and Trends
- 5.1.1. Growth Drivers
  - 5.1.1.1. Rising Prevalence of Chronic & Rare Diseases
  - 5.1.1.2. Innovation & High-Value Specialty Peptides
- 5.1.2. Restraints
  - 5.1.2.1. High Production Costs & Complex Manufacturing
  - 5.1.2.2. Stringent Regulatory Requirements
- 5.1.3. Opportunity
  - 5.1.3.1. Contract Manufacturing & CDMO Partnerships
- 5.1.4. Key Trends
  - 5.1.4.1. Shift Towards Personalized & Targeted Peptide Therapies
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 5.2.1. By Drug Class
  - 5.2.1.1. Key Insights
    - 5.2.1.1.1. Insulin & Insulin Analogs
    - 5.2.1.1.2. GLP-1 Receptor Agonists
    - 5.2.1.1.3. Growth Hormone Peptides
    - 5.2.1.1.4. Gonadotropin-releasing Hormone (GnRH) Analogs
    - 5.2.1.1.5. Somatostatin Analogs
    - 5.2.1.1.6. Parathyroid Hormone Peptides
    - 5.2.1.1.7. Calcitonin Peptides
    - 5.2.1.1.8. Vasopressin & Analogues
    - 5.2.1.1.9. ACTH Peptides
    - 5.2.1.1.10. Peptide-based Oncology Drugs
    - 5.2.1.1.11. Anti-infective Peptide Drugs
    - 5.2.1.1.12. Other Peptide Therapeutics
- 5.2.2. By Route of Administration
  - 5.2.2.1. Key Insights
    - 5.2.2.1.1. Subcutaneous Injection
    - 5.2.2.1.2. Intravenous Injection
    - 5.2.2.1.3. Intramuscular Injection
    - 5.2.2.1.4. Intrathecal Injection
    - 5.2.2.1.5. Other Injectable Routes
- 5.2.3. By Formulation Type
  - 5.2.3.1. Key Insights
    - 5.2.3.1.1. Ready-to-use Injectables
    - 5.2.3.1.2. Lyophilized Injectables
    - 5.2.3.1.3. Sustained/Extended-release Injectables
- 5.2.4. By Delivery System
  - 5.2.4.1. Key Insights
    - 5.2.4.1.1. Conventional Vials & Ampoules
    - 5.2.4.1.2. Prefilled Syringes
    - 5.2.4.1.3. Pen Injectors
    - 5.2.4.1.4. Auto-injectors
    - 5.2.4.1.5. Infusion-based Delivery Systems
- 5.2.5. By Therapeutic Area
  - 5.2.5.1. Key Insights
    - 5.2.5.1.1. Metabolic Disorders
    - 5.2.5.1.2. Endocrine Disorders
    - 5.2.5.1.3. Oncology
    - 5.2.5.1.4. Gastrointestinal Disorders
    - 5.2.5.1.5. Osteoporosis & Bone Disorders
    - 5.2.5.1.6. Cardiovascular Diseases
    - 5.2.5.1.7. Infectious Diseases
    - 5.2.5.1.8. Rare Diseases
    - 5.2.5.1.9. Others
- 5.2.6. By Distribution Channel
  - 5.2.6.1. Key Insights
    - 5.2.6.1.1. Hospital Pharmacies
    - 5.2.6.1.2. Retail Pharmacies
    - 5.2.6.1.3. Specialty Pharmacies
    - 5.2.6.1.4. Online Pharmacies
- 5.2.7. By End User
  - 5.2.7.1. Key Insights
    - 5.2.7.1.1. Hospitals
    - 5.2.7.1.2. Specialty Clinics
    - 5.2.7.1.3. Ambulatory Care Centers
    - 5.2.7.1.4. Homecare Settings
    - 5.2.7.1.5. Research & Academic Institutes
- 5.2.8. By Manufacturing Model
- 5.2.9. By Region
  - 5.2.9.1. Key Insights
    - 5.2.9.1.1. North America
      - 5.2.9.1.1.1. The U.S.
      - 5.2.9.1.1.2. Canada
      - 5.2.9.1.1.3. Mexico
    - 5.2.9.1.2. Europe
      - 5.2.9.1.2.1. Western Europe
        
        5.2.9.1.2.1.1. The UK
        5.2.9.1.2.1.2. Germany
        5.2.9.1.2.1.3. France
        5.2.9.1.2.1.4. Italy
        5.2.9.1.2.1.5. Spain
        5.2.9.1.2.1.6. Rest of Western Europe
      - 5.2.9.1.2.2. Eastern Europe
        
        5.2.9.1.2.2.1. Poland
        5.2.9.1.2.2.2. Russia
        5.2.9.1.2.2.3. Rest of Eastern Europe
    - 5.2.9.1.3. Asia Pacific
      - 5.2.9.1.3.1. China
      - 5.2.9.1.3.2. India
      - 5.2.9.1.3.3. Japan
      - 5.2.9.1.3.4. South Korea
      - 5.2.9.1.3.5. Australia & New Zealand
      - 5.2.9.1.3.6. ASEAN
        
        5.2.9.1.3.6.1. Indonesia
        5.2.9.1.3.6.2. Malaysia
        5.2.9.1.3.6.3. Thailand
        5.2.9.1.3.6.4. Singapore
        5.2.9.1.3.6.5. Rest of ASEAN
      - 5.2.9.1.3.7. Rest of Asia Pacific
    - 5.2.9.1.4. Middle East & Africa
      - 5.2.9.1.4.1. UAE
      - 5.2.9.1.4.2. Saudi Arabia
      - 5.2.9.1.4.3. South Africa
      - 5.2.9.1.4.4. Rest of MEA
    - 5.2.9.1.5. South America
      - 5.2.9.1.5.1. Argentina
      - 5.2.9.1.5.2. Brazil
      - 5.2.9.1.5.3. Rest of South America

Chapter 6. North America Injectable Peptides Drugs Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. By Drug Class
- 6.2.2. By Route of Administration
- 6.2.3. By Formulation Type
- 6.2.4. By Delivery System
- 6.2.5. By Therapeutic Area
- 6.2.6. By Distribution Channel
- 6.2.7. By End User
- 6.2.8. By Manufacturing Model
- 6.2.9. By Country

Chapter 7. Europe Injectable Peptides Drugs Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. By Drug Class
- 7.2.2. By Route of Administration
- 7.2.3. By Formulation Type
- 7.2.4. By Delivery System
- 7.2.5. By Therapeutic Area
- 7.2.6. By Distribution Channel
- 7.2.7. By End User
- 7.2.8. By Manufacturing Model
- 7.2.9. By Country

Chapter 8. Asia Pacific Injectable Peptides Drugs Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. By Drug Class
- 8.2.2. By Route of Administration
- 8.2.3. By Formulation Type
- 8.2.4. By Delivery System
- 8.2.5. By Therapeutic Area
- 8.2.6. By Distribution Channel
- 8.2.7. By End User
- 8.2.8. By Manufacturing Model
- 8.2.9. By Country

Chapter 9. Middle East & Africa Injectable Peptides Drugs Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. By Drug Class
- 9.2.2. By Route of Administration
- 9.2.3. By Formulation Type
- 9.2.4. By Delivery System
- 9.2.5. By Therapeutic Area
- 9.2.6. By Distribution Channel
- 9.2.7. By End User
- 9.2.8. By Manufacturing Model
- 9.2.9. By Country

Chapter 10. South America Injectable Peptides Drugs Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. By Drug Class
- 10.2.2. By Route of Administration
- 10.2.3. By Formulation Type
- 10.2.4. By Delivery System
- 10.2.5. By Therapeutic Area
- 10.2.6. By Distribution Channel
- 10.2.7. By End User
- 10.2.8. By Manufacturing Model
- 10.2.9. By Country